MCID: LRG008
MIFTS: 34

Large Granular Lymphocyte Leukemia

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Large Granular Lymphocyte Leukemia

MalaCards integrated aliases for Large Granular Lymphocyte Leukemia:

Name: Large Granular Lymphocyte Leukemia 58
T-Cell Large Granular Lymphocyte Leukemia 70
Leukemia, Large Granular Lymphocytic 70

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Orphanet 58 ORPHA512034
UMLS 70 C1522378 C1955861

Summaries for Large Granular Lymphocyte Leukemia

MalaCards based summary : Large Granular Lymphocyte Leukemia, also known as t-cell large granular lymphocyte leukemia, is related to felty syndrome and lymphoproliferative syndrome. An important gene associated with Large Granular Lymphocyte Leukemia is STAT3 (Signal Transducer And Activator Of Transcription 3), and among its related pathways/superpathways are Cytokine production by Th17 cells in CF (Mouse model) and IL-17 Family Signaling Pathways. The drugs Methotrexate and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include liver, bone marrow and nk cells.

Related Diseases for Large Granular Lymphocyte Leukemia

Diseases related to Large Granular Lymphocyte Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 135)
# Related Disease Score Top Affiliating Genes
1 felty syndrome 31.1 STAT3 CSF3
2 lymphoproliferative syndrome 30.5 STAT3 CD52 CASP8
3 aplastic anemia 29.9 STAT3 CSF3 CD52
4 myelodysplastic syndrome 29.6 STAT3 CSF3 CASP8
5 leukemia, chronic lymphocytic 29.6 STAT3 CSF3 CD52 CASP8
6 t-cell large granular lymphocyte leukemia 12.0
7 aggressive nk-cell leukemia 11.6
8 leukemia 10.9
9 neutropenia 10.9
10 splenomegaly 10.8
11 pure red-cell aplasia 10.7
12 hemolytic anemia 10.5
13 autoimmune disease 10.4
14 rheumatoid arthritis 10.4
15 deficiency anemia 10.4
16 thrombocytopenia 10.4
17 t-cell lymphoblastic leukemia/lymphoma 10.4
18 leukemia, t-cell, chronic 10.4
19 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
20 bacterial infectious disease 10.4
21 pancytopenia 10.4
22 agammaglobulinemia 10.4
23 hairy cell leukemia 10.3
24 47,xyy 10.3
25 granulocytopenia 10.3
26 anemia, autoimmune hemolytic 10.2
27 thymoma, familial 10.2
28 leukemia, acute myeloid 10.2
29 graft-versus-host disease 10.2
30 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.2
31 peripheral t-cell lymphoma 10.2
32 prolymphocytic leukemia 10.2
33 toxic shock syndrome 10.2
34 polyclonal hypergammaglobulinemia 10.2
35 thymoma 10.2
36 purpura 10.2
37 b-cell lymphoma 10.2
38 chronic nk-cell lymphocytosis 10.2
39 arthritis 10.2
40 acquired pure red cell aplasia 10.2
41 chromosomal triplication 10.2
42 lymphomatoid granulomatosis 10.2
43 t-cell prolymphocytic leukemia 10.2
44 opportunistic mycosis 10.1 STAT3 CSF3
45 myelopathy, htlv-1-associated 10.1
46 cyclic neutropenia 10.1
47 sarcoidosis 1 10.1
48 celiac disease 1 10.1
49 enterocolitis 10.1
50 myelofibrosis 10.1

Graphical network of the top 20 diseases related to Large Granular Lymphocyte Leukemia:



Diseases related to Large Granular Lymphocyte Leukemia

Symptoms & Phenotypes for Large Granular Lymphocyte Leukemia

Drugs & Therapeutics for Large Granular Lymphocyte Leukemia

Drugs for Large Granular Lymphocyte Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 93)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methotrexate Approved Phase 2, Phase 3 1959-05-2, 59-05-2 126941
2
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
3
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
4
Thalidomide Approved, Investigational, Withdrawn Phase 2, Phase 3 50-35-1 5426
5 Folic Acid Antagonists Phase 2, Phase 3
6 Dermatologic Agents Phase 2, Phase 3
7
Melphalan Approved Phase 2 148-82-3 4053 460612
8
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
9
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
10
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
11
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
12
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
13
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
14
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
15
Busulfan Approved, Investigational Phase 2 55-98-1 2478
16
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
17
alemtuzumab Approved, Investigational Phase 2 216503-57-0
18
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
19
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
20
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
21
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
22
Lenalidomide Approved Phase 2 191732-72-6 216326
23
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
24
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
25
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
26
tipifarnib Investigational Phase 2 192185-72-1 159324
27 Neuroprotective Agents Phase 2
28 Methylprednisolone Acetate Phase 2
29 gamma-Globulins Phase 2
30 Thymoglobulin Phase 2
31 Antilymphocyte Serum Phase 2
32 Rho(D) Immune Globulin Phase 2
33 Immunoglobulins Phase 1, Phase 2
34 Antibodies Phase 1, Phase 2
35 Antibodies, Monoclonal Phase 1, Phase 2
36 Antineoplastic Agents, Immunological Phase 2
37 Cyclosporins Phase 2
38 Antifungal Agents Phase 2
39 Liver Extracts Phase 2
40 Angiogenesis Inhibitors Phase 2
41 Protein Kinase Inhibitors Phase 2
42 Immunoconjugates Phase 1, Phase 2
43 Immunoglobulins, Intravenous Phase 1, Phase 2
44 Cola Phase 1, Phase 2
45
Bevacizumab Approved, Investigational Phase 1 216974-75-3
46
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
47
Bortezomib Approved, Investigational Phase 1 179324-69-7 93860 387447
48
Dasatinib Approved, Investigational Phase 1 302962-49-8 3062316
49
Vorinostat Approved, Investigational Phase 1 149647-78-9 5311
50
Etoposide Approved Phase 1 33419-42-0 36462

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Thalidomide Plus Prednisone and Methotrexate for the Symptomatic Large Granular Lymphocytic Leukemia - a Prospective Multicenter Clinical Trial From China Recruiting NCT04453345 Phase 2, Phase 3 thalidomide + prednisone + methotrexate
2 Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia Unknown status NCT01976182 Phase 2 Methotrexate;Cyclophosphamide
3 A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T-Cell Lymphoma Unknown status NCT03239392 Phase 1, Phase 2 BNZ132-1-40
4 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
5 Phase II Study of Cyclosporine in T-Cell Large Granular Lymphocytic Leukemia Completed NCT00031980 Phase 2 cyclosporine
6 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
7 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
8 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
9 Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial Completed NCT00104858 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
10 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
11 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
12 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
13 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
14 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
15 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies Active, not recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
16 First Line Therapy With Methotrexate (MTX) and Second Line Therapy With Fludarabine of Patients With T-Cell Large Granular Lymphocyte Leukemia (T-LGL) Terminated NCT00278265 Phase 2 MTX followed by fludarabine
17 Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL) Terminated NCT01191749 Phase 2 Alemtuzumab
18 Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia Terminated NCT00363779 Phase 2 Cyclosporine
19 A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis Terminated NCT00387426 Phase 2 sunitinib malate
20 A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas Terminated NCT01805037 Phase 1, Phase 2 brentuximab vedotin
21 A Phase 2 Study of Tipifarnib in Large Granular Lymphocyte (LGL) Leukemia Terminated NCT00360776 Phase 2 tipifarnib
22 A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA Terminated NCT01769222 Phase 1, Phase 2
23 A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab Terminated NCT01419795 Phase 2 lenalidomide
24 Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options Withdrawn NCT01652014 Phase 2 cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
25 A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients With Relapsed / Refractory Lymphoid Malignancies Completed NCT01094860 Phase 1 Nelarabine
26 Phase I Open-Label Single-Dose Study of Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R-Beta Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia Completed NCT00076180 Phase 1
27 PHASE I STUDY OF T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA USING THE MIK-BETA 1 MONOCLONAL ANTIBODY DIRECTED TOWARD THE IL-2R BETA SUBUNIT Completed NCT00019032 Phase 1
28 A Phase 1 Study of Lenalidomide Maintenance Following Allogeneic Hematopoietic Cell Transplantation in Patients With Select High Risk Hematological Malignancies Completed NCT01254578 Phase 1 Lenalidomide
29 Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin TM) in Combination With Escalating Doses of Oral AZD2171 for Patients With Advanced Malignancies Completed NCT00458731 Phase 1 cediranib maleate
30 A Phase I Study of MK-2206, an AKT Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01231919 Phase 1 Akt inhibitor MK2206
31 A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00025415 Phase 1 imatinib mesylate
32 Phase I Dose-Escalation Study of Azacitidine (Vidaza) and Bortezomib (Velcade) in T-Cell Lymphoma Completed NCT01129180 Phase 1 azacitidine;bortezomib
33 Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517) in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction Completed NCT00608361 Phase 1 Dasatinib
34 Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors Completed NCT01748721 Phase 1
35 A Phase 1/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy Completed NCT00890747 Phase 1 sunitinib malate
36 Phase I Study of the Aurora Kinase a Inhibitor MLN8237 in Combination With the Histone Deacetylase Inhibitor Vorinostat in Lymphoid Malignancies Completed NCT01567709 Phase 1 Alisertib;Vorinostat
37 A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
38 Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma Active, not recruiting NCT02168140 Phase 1 6,8-bis(benzylthio)octanoic acid;bendamustine hydrochloride
39 A Phase I Trial of the Combination of Oxaliplatin (NSC 266046, IND 57004), Ifosfamide, and Etoposide in Recurrent or Refractory Pediatric Solid Tumors and Lymphomas Terminated NCT00101205 Phase 1 oxaliplatin;etoposide
40 A PHASE 1/2 STUDY OF RO4929097, AN ORAL SMALL MOLECULE INHIBITOR OF GAMMA-SECRETASE, IN CHILDREN WITH RELAPSED/REFRACTORY SOLID OR CNS TUMORS, LYMPHOMA, OR T-CELL LEUKEMIA Terminated NCT01088763 Phase 1 gamma-secretase/Notch signalling pathway inhibitor RO4929097;dexamethasone
41 A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies Terminated NCT01678443 Phase 1
42 Allogeneic Hematopoietic Stem Cell Transplantation for Induction of Mixed Hematopoietic Chimerism in Patients Infected With Human Immunodeficiency Virus-1 Using a Non-Marrow Ablative Conditioning Regimen Containing Total Body Irradiation in Combination With Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00112593 fludarabine phosphate;cyclosporine;mycophenolate mofetil
43 Nonmyeloablative PBSC Allografting From HLA Matched Related Donors Using Fludarabine and/or Low Dose TBI With Disease-Risk Based Immunosuppression Completed NCT00014235 fludarabine phosphate;cyclosporine;mycophenolate mofetil
44 Low-Dose TBI and Fludarabine Followed by Unrelated Donor Stem Cell Transplantation for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-center Trial Completed NCT00005799 fludarabine phosphate;cyclosporine;mycophenolate mofetil
45 The TOUCH Project: Reducing Distress and Promoting Quality of Life Via Caregiver Massage of Children Undergoing Treatment for Cancer Completed NCT01053494
46 Modified Preemptive CMV Management Strategy After Allogeneic Hematopoietic Cell Transplantation and Laboratory Correlation With Innate Immune Function Completed NCT01199562 ganciclovir;valganciclovir;foscarnet sodium
47 Personalized Monitoring of Intravenous Busulfan Dosing for Patients With Lymphoma Undergoing Autologous Stem Cell Transplantation. Completed NCT01959477 Early Phase 1 busulfan;etoposide;cyclophosphamide
48 A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors Completed NCT00898079
49 Registry of the German CLL Study Group Long Term Follow-up of Patients With CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation Recruiting NCT02863692
50 A Study of Hematopoietic Stem Cell Supermobilization in Patients With Non-Hodgkin Lymphoma Terminated NCT01408043 plerixafor;etoposide

Search NIH Clinical Center for Large Granular Lymphocyte Leukemia

Genetic Tests for Large Granular Lymphocyte Leukemia

Anatomical Context for Large Granular Lymphocyte Leukemia

MalaCards organs/tissues related to Large Granular Lymphocyte Leukemia:

40
Liver, Bone Marrow, Nk Cells, T Cells, Spleen, Prostate, Myeloid

Publications for Large Granular Lymphocyte Leukemia

Articles related to Large Granular Lymphocyte Leukemia:

(show top 50) (show all 313)
# Title Authors PMID Year
1
CD8-positive cutaneous lymphoproliferation associated with large granular lymphocyte leukemia in a patient with X-linked agammaglobulinemia. 61
32885480 2021
2
Steady-State Design of Large-Dimensional Boolean Networks. 61
32287018 2021
3
Emerging Role of T-cell Receptor Constant β Chain-1 (TRBC1) Expression in the Flow Cytometric Diagnosis of T-cell Malignancies. 61
33673033 2021
4
Clonal hematopoiesis in adult pure red cell aplasia. 61
33500526 2021
5
Belinostat in Relapsed/Refractory T-Cell Large Granular Lymphocyte Leukemia. 61
32348994 2021
6
Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. 61
32919988 2020
7
FPGA Accelerated Analysis of Boolean Gene Regulatory Networks. 61
31494553 2020
8
Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. 61
32920324 2020
9
Large granular lymphocyte leukemia serum and corresponding hematological parameters reveal unique cytokine and sphingolipid biomarkers and associations with STAT3 mutations. 61
32710512 2020
10
Identification of a miR-146b-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia. 61
31467122 2020
11
Inclusion-body myositis and primary Sjögren syndrome: mechanisms for shared etiologies. 61
32035011 2020
12
Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. 61
31740810 2020
13
Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. 61
32035354 2020
14
[Clinical and laboratory analysis of 17 patients with γδT-cell large granular lymphocyte leukemia]. 61
32135626 2020
15
T-Cell Large Granular Lymphocyte Leukemia in a Patient With Rheumatoid Arthritis. 61
32646239 2020
16
Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia. 61
32133291 2020
17
Whole Genome Sequencing of Spontaneously Occurring Rat Natural Killer Large Granular Lymphocyte Leukemia Identifies JAK1 Somatic Activating Mutation. 61
31947841 2020
18
Dysfunction of immune system in the development of large granular lymphocyte leukemia. 61
30334691 2019
19
Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy. 61
31164030 2019
20
T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. 61
31585621 2019
21
T-cell large granular lymphocyte leukemia in solid organ transplant recipients: case series and review of the literature. 61
31250283 2019
22
[CD4(-)/CD8(-)/CD56(+)/TCRγδ(+) T-cell large granular lymphocyte leukemia presenting as aplastic anemia: a case report and literature review]. 61
31340629 2019
23
IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability. 61
30353031 2019
24
T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization. 61
30573508 2019
25
Subclonal STAT3 mutations solidify clonal dominance. 61
30898763 2019
26
T-cell large granular lymphocytic (LGL) leukemia consists of CD4+/CD8dim and CD4-/CD8+ LGL populations in association with immune thrombocytopenia, autoimmune neutropenia, and monoclonal B-cell lymphocytosis. 61
31866622 2019
27
Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia. 61
29963929 2019
28
[Hepatocellular failure revealing T-cell large granular lymphocyte leukemia: Morocco case study and literature review]. 61
31934260 2019
29
Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. 61
30455079 2018
30
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. 61
29473430 2018
31
Large granular lymphocytic leukemia CD3-CD56-: a challenge for the biologist and the physician. 61
30078779 2018
32
Management of T-cell large granular lymphocyte leukemia and concurrent retroperitoneal liposarcoma. 61
30057739 2018
33
Pure red cell aplasia with t-cell large granular lymphocytic leukemia. 61
29921385 2018
34
Donor derived T-cell large granular lymphocyte leukemia after cord blood transplant for pediatric T-cell lymphoblastic leukemia. 61
29269802 2018
35
Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. 61
29217783 2018
36
Next-Generation Sequencing Analysis of the Human TCRγδ+ T-Cell Repertoire Reveals Shifts in Vγ- and Vδ-Usage in Memory Populations upon Aging. 61
29559980 2018
37
Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. 61
29474442 2018
38
Protothecosis in a patient with T cell lymphocytic leukemia. 61
28554708 2017
39
Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia. 61
27715403 2017
40
Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach. 61
28167832 2017
41
A screening method with lymphocyte percentage and proportion of granular lymphocytes in the peripheral blood for large granular lymphocyte (LGL) leukemia. 61
27686672 2017
42
Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRγδ+ T cell large granular lymphocyte leukemia. 61
28407008 2017
43
Pure red cell aplasia. 61
27913462 2016
44
Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate. 61
27640075 2016
45
Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment. 61
27896231 2016
46
Pure red cell aplasia. 61
27881371 2016
47
T-Cell Large Granular Lymphocyte Leukemia in the Lower Eyelid. 61
25198396 2016
48
THE CASE OF T-CELL LARGE GRANULAR LYPHOCYTE LEUKEMIA PRESENTED AS TRANSFUSION DEPENDENT ANEMIA WITH SUSTAINED RESPONSE TO CYC- LOSPORINE A THERAPY: CASE REPORT. 61
29693864 2016
49
High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. 61
27697773 2016
50
Pyoderma Gangrenosum in the Urologist Clinic. 61
27867335 2016

Variations for Large Granular Lymphocyte Leukemia

Expression for Large Granular Lymphocyte Leukemia

Search GEO for disease gene expression data for Large Granular Lymphocyte Leukemia.

Pathways for Large Granular Lymphocyte Leukemia

Pathways related to Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.23 STAT3 CSF3
2
Show member pathways
11.13 STAT3 CSF3 CASP8
3 10.98 STAT3 CASP8
4 10.65 STAT3 CSF3

GO Terms for Large Granular Lymphocyte Leukemia

Biological processes related to Large Granular Lymphocyte Leukemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 response to estradiol GO:0032355 9.49 STAT3 CASP8
2 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.48 HCST CSF3
3 positive regulation of interleukin-6 production GO:0032755 9.46 TYROBP STAT3
4 positive regulation of tumor necrosis factor production GO:0032760 9.43 TYROBP STAT3
5 apoptotic signaling pathway GO:0097190 9.4 TYROBP CASP8
6 cellular response to organic cyclic compound GO:0071407 9.37 STAT3 CASP8
7 negative regulation of neuron death GO:1901215 9.32 STAT3 CSF3
8 cellular response to cytokine stimulus GO:0071345 9.26 STAT3 CSF3
9 positive regulation of neuron death GO:1901216 9.16 TYROBP CASP8
10 response to ethanol GO:0045471 9.13 STAT3 CSF3 CASP8
11 positive regulation of interleukin-1 beta production GO:0032731 8.8 TYROBP STAT3 CASP8

Sources for Large Granular Lymphocyte Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....